753 results on '"Monath, Thomas P."'
Search Results
2. Contributors
3. Sofosbuvir off-label treatment of yellow fever patients during an outbreak in Brazil, 2018, a cohort study
4. Yellow fever resurgence: An avoidable crisis?
5. Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile
6. Japanese Encephalitis: Risk of Emergence in the United States and the Resulting Impact
7. A short history of Lassa fever: the first 10–15 years after discovery
8. rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment
9. A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants
10. Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus disease
11. Yellow Fever
12. The Arboviruses: Epidemiology and Ecology
13. Western Equine Encephalomyelitis
14. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study
15. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic
16. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study
17. Epidemic arboviral diseases: priorities for research and public health
18. Japanese Encephalitis: Risk of Emergence in the United States and the Resulting Impact.
19. Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains
20. Reptile Rhabdoviruses
21. Contributors
22. Contributors
23. Yellow Fever Vaccines
24. Chikungunya and Zika: The Future
25. Characterization and Investigation of Risk Factors for Late-Relapsing Hepatitis After Yellow Fever.
26. Biographical Feature: Marc S. Collett (23 May 1951–11 June 2022): the Battle against Viral Disease Has Lost a Valiant Warrior, and the World Has Lost a Splendid Human Being
27. Live virus vaccines based on a yellow fever vaccine backbone: Standardized template with key considerations for a risk/benefit assessment
28. Estimation of the Minimal Rift Valley Fever Virus Protective Neutralizing Antibody Titer in Human Volunteers Immunized with MP-12 Vaccine Based on Protection in a Mouse Model of Disease
29. A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2
30. Recombinant, Chimeric, Live, Attenuated Vaccines Against Flaviviruses and Alphaviruses
31. Yellow Fever Vaccines: The Success of Empiricism, Pitfalls of Application, and Transition to Molecular Vaccinology
32. Vaccines to Prevent Coccidioidomycosis: A Gene-Deletion Mutant of Coccidioides Posadasii as a Viable Candidate for Human Trials
33. Yellow Fever
34. Chapter 64 - Yellow Fever Vaccine
35. Supplement to: A recombinant vesicular stomatitis virus Ebola vaccine.
36. ‘One Medicine−One Health’: An Historic Perspective.
37. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial
38. Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential
39. High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster
40. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
41. High neutralizing antibody levels against SARS-CoV-2 Omicron BA.1 and BA.2 after UB-612 vaccine booster
42. Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study
43. Development of Antigen-Specific Memory CD8⁺ T Cells Following Live-Attenuated Chimeric West Nile Virus Vaccination
44. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever
45. Interferon-γ-Mediated Antiviral Immunity against Orthopoxvirus Infection Is Provided by γδ T Cells [with Reply to Agrati et al]
46. A Live, Attenuated Recombinant West Nile Virus Vaccine
47. Flow-Cytometric Detection of Vaccinia-Induced Memory Effector CD4⁺, CD8⁺, and γδTCR⁺ T Cells Capable of Antigen-Specific Expansion and Effector Functions
48. The Challenge: Biotechnology Transfer to Public Health. Examples from Arbovirology
49. Activity of Selected Amaryllidaceae Constituents and Related Synthetic Substances Against Medically Important RNA Viruses
50. Helicobacter pylori Reinfection Is Common in Peruvian Adults after Antibiotic Eradication Therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.